The short answer
Liraglutide is a GLP-1 analogue with roughly 97% homology to the native hormone, modified with a C16 palmitic acid chain that binds albumin and extends its half-life to around 13 hours, enough for daily dosing. It is the generation between exenatide and semaglutide.
Key facts
- Class
- GLP-1 receptor agonist (peptide analogue)
- Developer
- Novo Nordisk
- Molecular weight
- ~3,751 Da
- Molecular formula
- C172H265N43O51
- PubChem CID
- 16134956
- Homology to native GLP-1
- ~97%
- Lipid chain
- C16 palmitic acid
- Dosing
- Once daily
The design step it represents
Exenatide showed that a protease-resistant GLP-1 receptor agonist worked. Liraglutide asked a different question: could the human hormone itself be modified rather than replaced by a lizard peptide? At roughly 97% homology to native GLP-1, it stays much closer to the original sequence than exenatide's 53%, and solves clearance by attaching a fatty acid rather than by substituting the whole molecule.
What the C16 chain does
Palmitic acid attached to the peptide binds reversibly to serum albumin. The bound complex is too large for glomerular filtration and is physically shielded from proteases, while a small free fraction remains available to engage the receptor. The result is a half-life of roughly 13 hours. A very large improvement on one to two minutes, and enough for once-daily dosing.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why semaglutide went weekly and liraglutide did not
Chain length. Liraglutide uses C16; semaglutide uses a C18 diacid attached through a longer γGlu-2xOEG linker, and also substitutes Aib at position 8 to block DPP-4 directly. Stronger albumin binding plus enzymatic protection moves the half-life from hours to about a week. The two molecules are the same strategy executed at different intensities.
Where it sits now
Liraglutide has been overtaken on effect size and convenience by weekly analogues, and by the dual and triple agonists beyond them. It retains historical significance as the first GLP-1 analogue derived from the human sequence rather than from venom, and as the compound that established albumin binding as the standard route to half-life extension in this class.
The pattern it established
Look at semaglutide, tirzepatide and retatrutide and the same feature appears in each: a fatty diacid chain for albumin binding, with length and linker tuned to the dosing interval required. Liraglutide is where that pattern starts. Understanding it explains the structural family resemblance across compounds targeting quite different receptors.
Quick reference
| Exenatide | Liraglutide | Semaglutide | |
|---|---|---|---|
| Origin | Gila monster venom | Human GLP-1 analogue | Human GLP-1 analogue |
| Homology to GLP-1 | ~53% | ~97% | ~94% |
| DPP-4 resistance | Natural (Gly2) | Partial | Aib8 substitution |
| Lipid chain | None | C16 palmitic | C18 diacid |
| Dosing | Twice daily / weekly | Once daily | Once weekly |
Frequently asked questions
Why is liraglutide daily rather than weekly?
Its C16 chain binds albumin less strongly than semaglutide's C18 diacid, and it lacks the Aib substitution that blocks DPP-4 directly. Half-life is around 13 hours rather than about a week.
Is liraglutide closer to human GLP-1 than exenatide?
Much closer, about 97% homology against exenatide's 53%. Exenatide is a different peptide that happens to fit the same receptor.
Is liraglutide still relevant?
It has been overtaken clinically, but it established albumin binding as the standard half-life extension strategy that every later compound uses.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Why Nausea and Efficacy Come From the Same MechanismGLP-1 slows gastric emptying and signals through the area postrema - the brainstem region governing both satiety and nausea. Why the two cannot be separated.
- Biased Agonism at the GLP-1 ReceptorTwo agonists at the same receptor can produce different outcomes by favouring cAMP over β-arrestin. Why tirzepatide internalises the receptor less than GLP-1.
- Albumin Binding and Half-Life ExtensionA fatty acid chain that binds albumin turns a peptide cleared in minutes into one dosed weekly. How chain length tunes it from liraglutide to retatrutide.
- What Is Pramlintide? The First Clinical Amylin AnaloguePramlintide solved amylin's aggregation problem with three prolines borrowed from rat amylin. Why it needed meal-time dosing and cagrilintide does not.
- What Is Oxyntomodulin? Nature's Dual AgonistOxyntomodulin is a gut peptide that activates both GLP-1 and glucagon receptors. It is the biological precedent every GLP-1/glucagon dual agonist is built on.